Neurological symptoms and blood neurofilament light levels.
biomarker
neurofilament
neurologic disease
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
04
03
2021
received:
06
02
2021
accepted:
08
03
2021
pubmed:
19
3
2021
medline:
13
7
2021
entrez:
18
3
2021
Statut:
ppublish
Résumé
Neurofilament light chain (NfL) is an incredibly specific marker of neuronal injury that is not specific for cause or location of the neuronal damage. NfL is increasingly considered as possible biomarker of disease activity in neurological conditions. Several works reviewed the utility of NfL in the different diseases. Nonetheless, NfL is a universal marker of neuronal damage, which interpretation spaces beyond the single disease. Because of this, the interpretation of NfL may benefit by also considering how neurological symptoms relate to its blood concentration. Here, we review how different neurological symptoms can be associated with blood NfL levels with a practical interpretation of it.
Substances chimiques
Biomarkers
0
Neurofilament Proteins
0
neurofilament protein L
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
13-20Subventions
Organisme : UK Dementia Research Institute at UCL
Organisme : Swedish State Support for Clinical Research
ID : ALFGBG-720931
Organisme : Alzheimer Drug Discovery Foundation (ADDF), USA
ID : 201809-2016862
Organisme : Schweizerischer Nationalfonds zur F&ö;rderung der Wissenschaftlichen Forschung
ID : P400PM_191077
Organisme : Swedish Research Council
ID : 2018-02532
Organisme : European Research Council
ID : 681712
Pays : International
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Barro C, Chitnis T, Weiner HL. Blood neurofilament light: a critical review of its application to neurologic disease. Ann Clin Transl Neurol. 2020;7(12):2508-2523. https://doi.org/10.1002/acn3.51234
Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577-589. https://doi.org/10.1038/s41582-018-0058-z
Körtvelyessy P, Kuhle J, Düzel E, et al. Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome. Annals of Clinical and Translational Neurology. 2020;7(11):2213-2220. https://doi.org/10.1002/acn3.51207
Disanto G, Barro C, Benkert P, et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857-870. https://doi.org/10.1002/ana.24954
Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54(10):1655-1661. https://doi.org/10.1515/cclm-2015-1195
Piehl F, Kockum I, Khademi M, et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler. 2018;24(8):1046-1054. https://doi.org/10.1177/1352458517715132
Sejbaek T, Nielsen HH, Penner N, et al. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients. J Neurol Neurosurg Psychiatry. 90(12), 1324-1330.
Bekinschtein T, Gleichgerrcht E, Manes F. Acute loss of consciousness. In: Handbook of Clinical Neurology. Vol 127. Elsevier; 2015:195-204. https://doi.org/10.1016/B978-0-444-52892-6.00013-1
Gattringer T, Pinter D, Enzinger C, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurol. 2017;89(20):2108-2114. https://doi.org/10.1212/WNL.0000000000004645
Shahim P, Gren M, Liman V, et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep. 2016;6(1):2045-2322. https://doi.org/10.1038/srep36791
Gravesteijn G, Rutten JW, Verberk IMW, et al. Serum Neurofilament light correlates with CADASIL disease severity and survival. Ann Clin Transl Neurol. 2019;6(1):46-56. https://doi.org/10.1002/acn3.678
Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020;11(1):812. https://doi.org/10.1038/s41467-020-14612-6
Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019;25(2):277-283. https://doi.org/10.1038/s41591-018-0304-3
Lin C-H, Li C-H, Yang K-C, et al. Blood NfL: A biomarker for disease severity and progression in Parkinson disease. Neurol. 2019;93(11):e1104-e1111. https://doi.org/10.1212/WNL.0000000000008088
Hansson O, Janelidze S, Hall S, et al. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurol. 2017;88(10):930-937. https://doi.org/10.1212/WNL.0000000000003680
Quiroz YT, Zetterberg H, Reiman EM, et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurol. 2020;19(6):513-521. https://doi.org/10.1016/S1474-4422(20)30137-X
Shahim P, Darin N, Andreasson U, et al. Cerebrospinal fluid brain injury biomarkers in children: a multicenter study. Pediatr Neurol. 2013;49(1):31-39. https://doi.org/10.1016/j.pediatrneurol.2013.02.015
Evers KS, Hügli M, Fouzas S, et al. Serum neurofilament levels in children with febrile seizures and in controls. Front Neurosci. 2020;14: https://doi.org/10.3389/fnins.2020.579958
Delcoigne B, Manouchehrinia A, Barro C, et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurol. 2020;94(11):e1201-e1212. https://doi.org/10.1212/WNL.0000000000009097
Kinney MO, Craig JJ, Kaplan PW. Non-convulsive status epilepticus: mimics and chameleons. Pract Neurol. 2018;18(4):291-305. https://doi.org/10.1136/practneurol-2017-001796
Grossman M, Irwin DJ. Primary progressive aphasia and stroke aphasia. Continuum (Minneap Minn). 2018;24:745-767. https://doi.org/10.1212/CON.0000000000000618
Steinacker P, Semler E, Anderl-Straub S, et al. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurol. 2017;88(10):961-969. https://doi.org/10.1212/WNL.0000000000003688
Hankey GJ. Stroke. Lancet. 2017;389(10069):641-654. https://doi.org/10.1016/S0140-6736(16)30962-X
Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3(1):17071. https://doi.org/10.1038/nrdp.2017.71
Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130-139. https://doi.org/10.1002/ana.25276
DeVere R. Disorders of taste and smell. Continuum (Minneap Minn). 2017;23(2):421-446.
Nordvig AS, Rimmer KT, Willey JZ, et al. Potential neurological manifestations of COVID-19. Neurol Clin Pract. 2020. https://doi.org/10.1212/CPJ.0000000000000897
Kanberg N, Ashton NJ, Andersson L-M, et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurol. 2020;95(12):e1754-e1759. https://doi.org/10.1212/WNL.0000000000010111
Barro C, Benkert P, Disanto G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018;141(8):2382-2391. https://doi.org/10.1093/brain/awy154
Modvig S, Degn M, Sander B, et al. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler. 2016;22(5):590-598. https://doi.org/10.1177/1352458515599074
Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13(1):83-99. https://doi.org/10.1016/S1474-4422(13)70259-X
Bagheri N, Mehta S. Acute vision loss. Prim Care. 2015;42(3):347-361. https://doi.org/10.1016/j.pop.2015.05.010
VIS group UK, Rowe F. Prevalence of ocular motor cranial nerve palsy and associations following stroke. Eye. 2011;25(7):881-887. https://doi.org/10.1038/eye.2011.78
Serra A, Chisari CG, Matta M. Eye movement abnormalities in multiple sclerosis: pathogenesis, modeling, and treatment. Front Neurol. 2018;9:31. https://doi.org/10.3389/fneur.2018.00031
Bathla G, Hegde AN. The trigeminal nerve: an illustrated review of its imaging anatomy and pathology. Clin Radiol. 2013;68(2):203-213. https://doi.org/10.1016/j.crad.2012.05.019
Jones MR, Urits I, Ehrhardt KP, et al. A comprehensive review of trigeminal neuralgia. Curr Pain Headache Rep. 2019;23(10):74. https://doi.org/10.1007/s11916-019-0810-0
Gupta S, Mends F, Hagiwara M, Fatterpekar G, Roehm PC. Imaging the facial nerve: a contemporary review. Radiology Research and Practice. 2013;2013:1-14. https://doi.org/10.1155/2013/248039
Landau M, Barner K. Vestibulocochlear nerve. Semin Neurol. 2009;29(01):66-73. https://doi.org/10.1055/s-0028-1124024
Choi J-Y, Lee S-H, Kim J-S. Central vertigo. Curr Opin Neurol. 2018;31(1):81-89. https://journals.lww.com/co-neurology/Fulltext/2018/02000/Central_vertigo.13.aspx
LeWitt PA, Kymes S, Hauser RA. Parkinson disease and orthostatic hypotension in the elderly: recognition and management of risk factors for falls. Aging Dis. 2020;11(3):679. https://doi.org/10.14336/AD.2019.0805
Sandelius Å, Zetterberg H, Blennow K, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurol. 2018;90(6):e518-e524. https://doi.org/10.1212/WNL.0000000000004932
Altmann P, De Simoni D, Kaider A, et al. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome. J Neuroinflammation. 2020;17(1):86. https://doi.org/10.1186/s12974-020-01737-0
Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurol. 2018;90(1):e22-e30. https://doi.org/10.1212/WNL.0000000000004761
Klockgether T. Sporadic ataxia with adult onset: classification and diagnostic criteria. Lancet Neurol. 2010;9(1):94-104. https://doi.org/10.1016/S1474-4422(09)70305-9
Wilke C, Bender F, Hayer SN, et al. Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. J Neurol. 2018;265(7):1618-1624. https://doi.org/10.1007/s00415-018-8893-9
The EFACTS study group, Hayer SN, Liepelt I,, et al. NfL and pNfH are increased in Friedreich's ataxia. J Neurol. 2020;267(5):1420-1430. https://doi.org/10.1007/s00415-020-09722-6
Wilke C, Haas E, Reetz K, et al. Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Mol Med. 2020;12(7):e11803. https://doi.org/10.15252/emmm.201911803
Elias WJ, Shah BB. Tremor. JAMA. 2014;311(9):948-954. https://doi.org/10.1001/jama.2014.1397
Byrne LM, Rodrigues FB, Blennow K, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurol. 2017;16(8):601-609. https://doi.org/10.1016/S1474-4422(17)30124-2
Kim S-H, Choi MK, Park NY, et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep. 2020;10(1):7995. https://doi.org/10.1038/s41598-020-64511-5
Xu S-Y, Li Z-X, Wu X-W, Li L, Li C-X. Frequency and pathophysiology of post-seizure Todd's paralysis. Med Sci Monit. 2020;26:e920751-1-e920751-4. https://doi.org/10.12659/MSM.920751
Park K, Tanaka K, Tanaka M. Uhthoff's phenomenon in multiple sclerosis and neuromyelitis optica. Eur Neurol. 2014;72(3-4):153-156. https://doi.org/10.1159/000361045
Watanabe M, Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019;93(13):e1299-e1311. https://doi.org/10.1212/WNL.0000000000008160